CHMP positive decision for Kadcyla, and approval in Japan
The cancer drug Kadcyla (trastuzumab emtansine) has today received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of people with HER2-positive metastatic breast cancer who had previously received Herceptin (trastuzumab) and a taxane chemotherapy.
Kadcyla consists of Swiss drug major Roche’s (ROG: SIX) trastuzumab antibody (Herceptin) and US drug developer ImmunoGen’s (Nasdaq: IMGN), DM1 cytotoxic agent. The DM1 is attached to the antibody using one of ImmunoGen’s linkers. Blockbuster Herceptin, which generated first-half 2013 sales of 3.08 billion Swiss francs ($3.3 billion), could face biosimilar competition as soon as 2016, and it is hoped that Kadcyla will help mitigate in ensuing revenue loss.
Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze